CureVac (NASDAQ:CVAC – Get Free Report) released its earnings results on Tuesday. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02, reports. The company had revenue of $17.94 million during the quarter, compared to analysts’ expectations of $15.01 million.
CureVac Stock Down 0.9 %
Shares of CVAC opened at $5.48 on Friday. CureVac has a twelve month low of $4.95 and a twelve month high of $12.79. The company has a current ratio of 3.86, a quick ratio of 3.72 and a debt-to-equity ratio of 0.05. The business’s 50-day moving average price is $6.31 and its 200-day moving average price is $8.33.
Hedge Funds Weigh In On CureVac
Hedge funds have recently bought and sold shares of the company. US Bancorp DE boosted its holdings in CureVac by 47.5% in the 1st quarter. US Bancorp DE now owns 3,693 shares of the company’s stock valued at $26,000 after purchasing an additional 1,189 shares during the period. Signaturefd LLC boosted its stake in CureVac by 459.5% during the second quarter. Signaturefd LLC now owns 5,338 shares of the company’s stock valued at $56,000 after buying an additional 4,384 shares during the period. China Universal Asset Management Co. Ltd. grew its position in CureVac by 95.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock worth $39,000 after buying an additional 2,804 shares in the last quarter. Optiver Holding B.V. increased its stake in CureVac by 2,407.0% in the 3rd quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock worth $47,000 after acquiring an additional 6,571 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of CureVac in the 1st quarter valued at about $59,000. Hedge funds and other institutional investors own 15.76% of the company’s stock.
Analyst Ratings Changes
CureVac Company Profile
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.
- Five stocks we like better than CureVac
- P/E Ratio Calculation: How to Assess Stocks
- Williams-Sonoma is a steal for buy-and-hold investors
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- A closer look at Warren Buffett’s latest surprise purchase
- The Role Economic Reports Play in a Successful Investment Strategy
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.